CRISPR Gene Therapy for Sickle Cell and Thalassemia Shows Strong Efficacy, but Long-Term Safety Questions Remain
A systematic review of 21 studies finds CRISPR/Cas9 therapies for beta-thalassemia and sickle cell disease achieve high transfusion independence and ...
